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OBJECTIVES: Glaucoma is a condition affecting one or
both eyes with raised intraocular pressure (IOP). Target
IOP should be reduced to 15mmHg to prevent progres-
sion of visual ﬁeld loss. The objective of the present study
was to perform and compare two country-speciﬁc cost-
effectiveness analyses of bimatoprost 0.03% (Lumigan)
compared with latanoprost 0.005% (Xalatan) as a
second-line mono-therapy for glaucoma patients in
Austria and Finland. METHODS: Revealing identical
practice patterns in glaucoma treatment in Austria and
Finland a decision model based on effectiveness and
resource-use data from a multinational RCT was con-
structed. The RCT covered 269 adult patients with inad-
equately controlled IOP. In the model country-speciﬁc
unit costs were used and cost-effectiveness was analysed
from a societal perspective within a 12-months time
horizon. The measure of effectiveness was “patients
achieving target IOP”. To handle uncertainty sensitivity
analyses (one-way, break-even, extreme scenario) were
undertaken. RESULTS: The RCT showed that 36% of
the patients using bimatoprost achieved target IOP
opposed to 22% using latanoprost. In the Austrian cost-
effectiveness analysis bimatoprost (€2279 per patient
achieving target IOP) showed to be cost-effective com-
pared with latanoprost (€3917). With nearly identical
ratios the same result appeared for Finland (bimatoprost:
€2317; latanoprost: €3998). The relative decrease in the
costs using bimatoprost was therefore 42% in both coun-
tries per patient achieving target IOP. The major reason
to this difference was the extra need for adjunctive ther-
apies using latanoprost. For all IOP-target levels in the
range 12–18mmHg bimatoprost was cheaper and more
effective (dominating strategy). CONCLUSION: Bimato-
prost showed to be a more cost-effective second-line
mono-therapy for glaucoma treatment in Austria and
Finland. The study furthermore showed that at least for
the two countries it seems possible to transfer cost-
effectiveness results between countries and still arrive at
the same recommendations for decision-making.
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OBJECTIVE: To assess the cost-effectiveness of photo-
dynamic therapy (PDT) with verteporﬁn as treatment for
subfoveal choroidal neovascularisation (CNV) with small
lesions (4 macular photocoagulation study disc areas),
relative to no treatment. METHODS: This analysis
assesses the cost-effectiveness of PDT using verteporﬁn in
patients with small subfoveal CNV lesions, based on
results of two multicentre, double-blind, randomised,
placebo-controlled trials (VIP and TAP). Data on visual
acuity were collected for 24–48 months. Patients with
visual acuity scores above the level of legal blindness in
Australia (which is 34 letters) were deﬁned as not blind.
The proportion of patients not blind at each three-month
interval was plotted on a “vision curve”, which was
extrapolated to 84 months. The area under this curve was
calculated for each group. The difference in the area
under the curve between groups represents the vision-
years gained from treatment. A costing analysis was per-
formed, based on an average of 3.4 treatments in the ﬁrst
year, 2.2 in the second year, 1.3 in the third year and 0.4
in the fourth year. Costs of nursing home, home and com-
munity care, falls and the disability pension considered to
be due to visual decline were also included. RESULTS:
Treatment using PDT with verteporﬁn results in a cost
saving, relative to no treatment, of between $2909 and
$4992 over the 7-year period, depending on assumptions
made in the extrapolation of trial data. Over this period,
between 1.801 and 2.194 vision-years were gained.
Therefore, PDT with verteporﬁn is both less expensive
and more effective than no treatment in this population.
Sensitivity analyses demonstrated these results were
robust to changes in the value of key variables. CON-
CLUSIONS: PDT with verteporﬁn represents a cost-
effective intervention in the proposed population. There
is currently no alternative therapy for patients with small
subfoveal CNV lesions.
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OBJECTIVES: Cataract is a major cause of blindness and
of severe visual impairment leading to bilateral blind-
ness in an estimated 20 million people worldwide. In
developing countries 50–90% of all blindness is due 
to cataract. There are several possible approaches to
removal of the cataract. This paper reports estimates of
the population health effects, costs and cost-effectiveness
of selected interventions in cataract surgery to restore eye-
sight in areas of the world with different epidemiologic
proﬁles. METHODS: Effectiveness estimates are based on
literature review taking into account factors such as oper-
